Clinical trial
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple…
NCT00319865 · Korean Multiple Myeloma Working Party, Other · Unknown status
Key facts
| NCT number | NCT00319865 |
|---|---|
| Title | PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma |
| Official title | PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Korean Multiple Myeloma Working Party, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Velcade, Thalidomide, Adriamycin, Dexamethasone |
| Enrollment | 47 |
| Start date | Nov 1, 2005 |
| Completion | Sep 1, 2008 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 27, 2006 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: